The Reporter Magazine
Friday, October 30, 2026
No Result
View All Result
  • Agenda
  • Interview
  • Editorial
  • Features
  • Money Talks
  • Global Addis
  • Economy
  • Travel
  • Art & Culture
  • Op-ed
  • The Month in Brief
  • Commentary
  • Watchdog
  • Sponsored
The Reporter Magazine
No Result
View All Result

Local Pharma Production Is a Matter of Sovereignty: Dr. Mohammed Nuri

Mahlet MehdibyMahlet Mehdi
October 8, 2026
Local Pharma Production Is a Matter of Sovereignty: Dr. Mohammed Nuri
Share on FacebookShare on X
ADVERTISEMENT

Dr. Mohammed Nuri Osman has spent nearly three decades in Ethiopia’s pharmaceutical industry. A physician by training, he transitioned into business to work across retail, importing and distribution, local manufacturing, and joint-venture investment.

Over the years, his leadership has encompassed Medtech Ethiopia, Julphar Ethiopia—established in partnership with Gulf Pharmaceutical Industries—and the Ethiopian Pharmaceuticals Manufacturing Share Company (EPHARM), where he serves as Board Chairman. His career spans the full spectrum of the domestic market, from commercial distribution to large-scale manufacturing.

That experience coincides with Ethiopia’s long-standing effort to build a self-reliant pharmaceutical manufacturing base. Yet despite recent growth, domestic producers remain heavily reliant on imported active pharmaceutical ingredients (APIs) and specialized inputs, with many operating well below installed capacity as imports continue to meet the bulk of national demand.

RELATED POSTS

Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations:  Security Analyst

Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations: Security Analyst

September 28, 2026
Competition, Trapped Funds, and Connectivity: Aviation Guru on Realities in a Fast-Evolving Industry

Competition, Trapped Funds, and Connectivity: Aviation Guru on Realities in a Fast-Evolving Industry

September 5, 2026

Mercy Corps Rethinks Humanitarian Approach as Funding Runs Dry

August 5, 2026

Beyond Lifting the Credit Cap

July 22, 2026

“The Violence is more Visible, more Chaotic, and Harder for the International Community to Ignore,” ECLJ.

July 1, 2026

Election Funding has Declined Significantly: Head ofCSOs Coalition for Elections

May 30, 2026

In this interview with The Reporter Magazine’s Mahlet Mehdi, Dr. Mohammed discusses the evolution of Ethiopia’s pharmaceutical sector, the technical realities of local manufacturing, procurement policies, EPHARM’s expansion at the Kilinto Industrial Park, and the strategic prospects for API production. EXCERPT:

The Reporter Magazine: You trained as a physician, but went on to build much of your career in pharmaceuticals and the healthcare business. What led you from clinical medicine into this side of the health sector?

Dr. Mohammed Nuri: I graduated with my medical degree nearly 30 years ago, but I only worked in clinical medicine for about a year. The main reason goes back to when I was a first-year university student nearly 30 years ago. My mother suddenly fell ill and underwent surgery. During her treatment, she urgently needed a powerful antibiotic called vancomycin. Interestingly, years later, my own company would go on to import that exact medication. But at the time, vancomycin was nowhere to be found in Ethiopia, and because it was unavailable, my mother lost her life.

That tragic experience stayed with me. I felt a deep sense of frustration and kept asking myself: how could my mother die simply because a medicine was unavailable? To me, it exposed how inadequate our national pharmaceutical supply system was.

Coming from a low-income family, I did not have the financial means to leave medical school and immediately start a business. So, at that young age, I made a firm decision: I would complete my seven years of medical education, but after graduating, I would enter pharmaceutical importing and eventually build the kind of enterprise I lead today. That became my primary goal.

After graduation, I was offered an opportunity to stay at my alma mater—what was then the Jimma Institute of Health Sciences, now Jimma University—as a lecturer. Instead, I took a major risk: I declined the post, moved to Addis Ababa, and entered the business world.

Having no initial capital, I simply joined some old friends who were traveling back and forth to Dubai. For about a year, I engaged in general trade to build up savings. Within that year, I opened my first retail pharmacy, and by the following year, I expanded into pharmaceutical importing.

You have worked across pharmaceutical importing, distribution, local manufacturing, and joint-venture manufacturing. Looking at the sector today, how different is Ethiopia’s pharmaceutical industry from when you first entered it? What has improved, and what major challenges remain?

What I am talking about now goes back around 25 years. At that time, the pharmaceutical sector—particularly pharmaceutical manufacturing—was at a very low level.

In fact, the very few companies involved in pharmaceutical manufacturing were closing. I remember factories producing IV fluids, including glucose solutions, and perhaps one or two other facilities. But the overall environment for pharmaceutical manufacturing was not conducive, as the sector had not been given the special attention it required. That was the situation when I entered this field.

One of the companies I later brought into Ethiopia through a joint venture was Gulf Pharmaceutical Industries, known as Julphar. The factory was established in the Jakros area. The United Arab Emirates is made up of seven emirates, and one of them is Ras Al Khaimah. Julphar is a company from Ras Al Khaimah, associated with the royal family there.

We initially worked as Julphar’s agent for several years. After that, we entered into a joint venture with them and jointly established a pharmaceutical factory in Ethiopia that is still operating today. We opened it around 13 years ago; then–Prime Minister Hailemariam Desalegn inaugurated it, and it received major media coverage at the time.

At the time, people said the investment changed the pharmaceutical manufacturing sector because manufacturers had been closing and there were many indications that manufacturing medicines in Ethiopia was extremely difficult. But after we convinced our partners to come and established the factory, the pharmaceutical sector started becoming more active, and the government began introducing certain incentives.

Pharmaceutical manufacturing is very difficult and unlike ordinary manufacturing; there are many ups and downs. For a foreign investor in particular, coming into such an environment and establishing a factory is not easy. So, when we did it, we set an example. After that, other investors came, including Indian investors, and local investors also began entering pharmaceutical manufacturing.

The situation was in its infancy when I started, and if you ask me how it is now, I would say it has barely moved beyond that. Ethiopia has not yet reached the level of pharmaceutical manufacturing that it deserves. Because of my work, I have traveled to many countries and personally seen more than 100 pharmaceutical factories. When I look at Ethiopia from that perspective, we are better than we were before, but we are still below the level we should have reached.

There is a lot of discussion today about expanding local pharmaceutical production. From your experience, what does ‘locally manufactured’ actually mean in the Ethiopian context? For a typical medicine produced here, which stages happen locally and which major inputs must still be imported?

This has to be very clear. When we say a locally manufactured medicine, we mean a medicine manufactured in the same way medicines are manufactured elsewhere in the world.

Sometimes people think pharmaceutical manufacturing means bringing a medicine in bulk and simply packaging it here. That is secondary packaging, and that is not what I am talking about.

What we are doing in Ethiopia is pharmaceutical manufacturing starting from active pharmaceutical raw materials. The raw materials themselves are generally not produced here; they come from abroad. We import the raw materials, formulate the product here, manufacture it using our own professionals, and undertake local quality control. Some packaging materials may be sourced locally while others are imported, but product development, research and development (R&D), and the complete manufacturing process take place here. So, what we have is full-fledged pharmaceutical manufacturing.

There are also processes known as secondary and tertiary packaging, where a finished product arrives from elsewhere and is simply placed into another package or box. I would not call that pharmaceutical manufacturing in the sense I am describing. The pharmaceutical manufacturing we conduct in Ethiopia follows the exact same standard definition used internationally.

For example, one of the strongest departments in my factory—and in pharmaceutical manufacturing generally—is Research and Development (R&D). There are many professionals in that department conducting different types of research. In earlier periods internationally, some testing was carried out on animals until those practices evolved or stopped. The point is that medicines must be studied according to strict standards. Their side effects and other parameters are evaluated, and production must adhere rigorously to those standards.

It does not end with manufacturing. After production, there is post-market assessment to check whether the medicine continues to meet its required specifications. This is not conducted solely by the manufacturer; independent pharmaceutical regulators also perform testing in certified laboratories.

So, the issue in Ethiopia is not whether what we are doing can be called true pharmaceutical manufacturing. The major issue is scale.

As we speak today, Ethiopia has only around 12 pharmaceutical factories for a population of nearly 140 to 150 million people. And even among those 12, almost half involve foreign investors—either fully foreign-owned or structured through joint ventures like ours. The number of pharmaceutical factories wholly owned by domestic investors is even smaller.

I know the Kenyan pharmaceutical market closely. Kenya has more than 80 pharmaceutical factories, while its population is roughly one-third of ours.

 

Studies show that many Ethiopian pharmaceutical manufacturers operate far below their installed capacity. What are the primary constraints driving this underutilization today?

That is correct. Most domestic manufacturers operate below capacity. My own factory used to operate at under 50 percent capacity, though over the past two years, conditions have gradually improved and we have reached roughly 60 to 65 percent.

Other factories in Ethiopia face similar struggles. The main constraint is the difficulty of sourcing inputs. The second—particularly under the previous foreign-exchange regime—has been limited access to hard currency.

 

Almost all Active Pharmaceutical Ingredients (APIs) are imported—there is not a single company producing them in Ethiopia. API manufacturing is far more sophisticated, and even across East Africa, capacity is extremely limited; South Africa is one of the few exceptions on the continent.

Pharmaceutical raw materials are fundamentally different from ordinary inputs. You cannot simply buy them from any available factory. We source strictly from pre-inspected, approved manufacturers. Finding the exact raw material you need when you need it is difficult, and Ethiopia’s import processes frequently cause delays.

Access to foreign currency has been a second major obstacle. Although the pharmaceutical sector was nominally prioritized for foreign-currency allocation, in practice we rarely experienced that priority to the degree required. We have, however, seen some improvement following recent foreign-exchange reforms.

A third critical challenge is finance. Pharmaceutical manufacturing is exceptionally capital-intensive, requiring substantial amounts of both foreign exchange and local currency. Unlike importing a finished product—which can be sold immediately to turn over capital—pharmaceutical production involves an extended lifecycle.

What is the business case for manufacturing medicines in Ethiopia rather than importing finished products? When does local production make economic sense, and under what circumstances is importing finished medicine still cheaper?

Yes, there is a business case. But before addressing the economics, it is important to recognize that domestic pharmaceutical manufacturing has a significance that transcends business: national health security and sovereignty.

During health emergencies, local capacity is critical. A few years ago, Ethiopia faced a severe outbreak of acute watery diarrheal disease in the Amhara region and southern parts of the country. Containing it required vast quantities of Oral Rehydration Salts (ORS)—a simple product, but a vital one. In a crisis, relying on overseas supply chains means losing precious time and lives. Having domestic factories allowed us to respond immediately. As our Prime Minister has noted, after food and clothing, a nation’s sovereignty depends on its ability to manufacture its own medicines.

From an economic perspective, local manufacturing often lowers costs by capturing scale and bypassing the compounded margins and shipping costs built into imported finished products. When you manufacture locally—particularly in larger volumes—you can avoid some of the costs already built into that finished imported product, which includes the foreign supplier’s profit margin and additional expenses.

So, in many cases, local manufacturing brings the price down.

However, that does not mean every locally manufactured medicine will automatically be cheaper. There are cases where it will not be, and the reason is economies of scale.

Ethiopia’s manufacturing capacity and China’s manufacturing capacity are not the same. A manufacturer in China may produce a particular product in enormous quantities. When you produce at that scale, the unit cost falls. So, even after transporting the product to Ethiopia and adding a profit margin, it may still reach our market at a price with which we cannot compete.

It is therefore important to be clear: stating that a locally manufactured medicine will always be cheaper, or that an imported one will always be more expensive, is not an absolute rule. In my experience, it varies from product to product. For many items, domestic manufacturing reduces the price. But for products that are not needed in large quantities, we manufacture only small batches because we supply mainly our domestic market and do not yet export at scale. A factory in India or China, on the other hand, distributes to many countries and manufactures in huge volumes. For those products, we cannot compete on price.

Ultimately, the major benefit of producing medicines domestically goes beyond price—it is a matter of national sovereignty. For a country to stand on its own, it needs the capacity to manufacture its own medicines and become self-reliant. That is the fundamental logic.

If APIs, other pharmaceutical ingredients, packaging materials, machinery, and other inputs still require foreign currency, how much does local manufacturing actually reduce Ethiopia’s forex requirements? Could you give us a practical example using a medicine you know well?

It does reduce it. The key lies in the cost difference between raw materials and finished products. Active ingredients and packaging materials are purchased in bulk at a much lower unit price. When you import a finished medicine, you aren’t just paying for the drug—you are paying foreign currency for the overseas labor, energy, overhead, profit margin, and external packaging added abroad. By importing raw materials and manufacturing locally, we keep those value-added costs and the currency needed to pay for them within Ethiopia.

Take paracetamol, a high-demand medicine everyone knows. When an importer brings in finished paracetamol tablets, every single stage of production is settled in foreign exchange. But when we produce it locally, we import only the bulk API and essential inputs from vetted suppliers at competitive prices. We handle the processing, quality testing, and packaging domestically using local currency.

While this logic applies to the majority of pharmaceuticals, it is especially critical for essential medicines—the basic antibiotics, analgesics, oral rehydration salts, and chronic care drugs that make up roughly 80 percent of Ethiopia’s daily healthcare needs. Because these foundational drugs are consumed in large volumes, manufacturing them domestically yields major foreign-exchange savings compared to importing finished units.

There are exceptions, such as highly specialized, low-volume medicines that remain cheaper to import due to economies of scale. But for the core 80 percent of medicines our population relies on every day, local manufacturing is vital for conserving foreign currency and ensuring continuous supply.

How important is government procurement—particularly through EPSS—to the viability of local pharmaceutical manufacturers? From a manufacturer’s perspective, what is currently working in the procurement system, and what needs to improve?

Government procurement through EPSS is extremely important for local manufacturers and has been a cornerstone of our industry’s growth. EPSS has implemented several supportive policies that provide crucial backing to domestic producers. First, for a growing list of essential medicines, the government now mandates that if a product can be manufactured domestically, it must be procured locally rather than imported. Second, to help domestic plants compete against massive foreign producers, EPSS applies a price preference margin of up to 25 percent for local manufacturers, which provides a significant competitive cushion. Finally, EPSS provides an upfront advance payment of 30 percent on procurement contracts. This liquidity is critical because it allows us to secure bulk raw materials and cover early operational costs without choking our cash flow. Overall, EPSS has continuously refined its operations and remains a primary anchor client for domestic producers, directly enabling our company’s expansion and operational stability.

Your experience spans pharmaceutical importing, distribution, and manufacturing. What have these different ventures taught you about pharmaceutical investment in Ethiopia—particularly the trade-offs between importing medicines and manufacturing them locally?

Importing is relatively straightforward—it is just one link in the broader pharmaceutical supply chain. You secure foreign currency, register the product, and import it. When we manufacture locally, we step into the role of the foreign supplier: other distributors who meet regulatory standards purchase from us just as we purchase from overseas plants when importing.

However, pharmaceutical manufacturing is a completely different endeavor. In my view, it is something you must approach with deep passion, dedication to your work, and a genuine commitment to national service—it cannot be treated as a mere commercial transaction.

Manufacturing is far more challenging than importing. It is capital-intensive, foreign-exchange reliant, knowledge-driven, and requires immense patience. It is inherently complex. Yet, the sense of fulfillment it offers is unmatched. Seeing a medicine you produced on a pharmacy shelf bearing the mark “Made in Ethiopia” brings a profound sense of national pride.

That pride drives our continuous investment and expansion, even with all the industry’s challenges. While our other businesses help support this financially, pharmaceutical manufacturing remains our core focus—the area where we will continue to strengthen and expand.

EPHARM is expanding its manufacturing footprint at the Kilinto Industrial Park. What new medicines or production capabilities will it introduce?

It is true that we are currently undertaking a massive expansion of EPHARM at the Kilinto Industrial Park, which is over 75 percent complete and set to become one of the country’s largest pharmaceutical facilities. Beyond Kilinto, we are building another new factory, as well as a specialized EPHARM unit designed to manufacture advanced drug formulations never before produced in Ethiopia.

The primary goal goes back to the broader national context: the number of pharmaceutical manufacturers in Ethiopia remains nowhere near what a country of our size requires, and local production capability is still in its infancy. With a growing population, demand for medicines is rising rapidly, yet the range of locally produced drugs remains very narrow. Our Kilinto expansion directly addresses these gaps through three core objectives. First, we are expanding our range and technical capabilities by scaling up beta-lactam antibiotic production and introducing complex formulations previously unavailable domestically—such as specialized combinations like Augmentin and injectable beta-lactam formulations, both of which were previously entirely dependent on imports. Second, the facility will dramatically increase our overall manufacturing capacity across key product lines to help meet domestic demand. Third, we are positioning EPHARM to compete beyond our borders. Under our agreement within Kilinto Industrial Park, we have a 25 percent export target to supply neighboring countries, which is why the facility is being built under the supervision of international consultants to meet stringent global standards, including international Good Manufacturing Practice (GMP) certification. Ultimately, our strategy extends beyond basic import substitution to build a high-standard, export-ready manufacturing hub.

 

Could you pick a locally manufactured medicine and walk us through its entire journey? Where do the active pharmaceutical ingredients and other key inputs come from, what happens inside the Ethiopian facility, and how does the final product reach the patient?

A good example is Flu Stop Plus, a widely used cold remedy that combines four active pharmaceutical ingredients: paracetamol, chlorpheniramine, pseudoephedrine, and caffeine. The manufacturing process begins with strict vendor qualification. We only source raw materials from our registered vendor list—suppliers whose facilities have been inspected, certified, and approved by our team and the Ethiopian pharmaceutical regulator. Once suppliers are selected, we secure foreign exchange, open a letter of credit, and import the ingredients alongside essential excipients like binders, fillers, and stabilizing agents that give the medicine its physical structure.

Logistics and quality assurance form the next critical stage. Imported materials arrive by air or sea and are immediately placed in quarantine within our warehouse. Before anything enters the production line, our Quality Control department samples and tests every raw material in our laboratory to verify purity and compliance with exact specifications. Once cleared, the precise quantities dictated by our standard manufacturing procedures are weighed and released to automated production machinery, minimizing direct human handling. After each batch cycle is complete, the entire production line undergoes thorough cleaning before the next run.

The final stage ensures safety and efficacy before the medicine reaches patients. After the tablets are processed and sealed into strip packaging, Quality Control pulls random samples from the finished batch for a second round of rigorous laboratory testing. We test for microbial contamination, dosage accuracy, weight uniformity, and chemical stability. Only after Quality Control issues a formal release certification is the product transferred from the warehouse to our sales and distribution channels, ultimately reaching pharmacies and patients across the country.

What would it take for Ethiopia to move beyond basic secondary formulation toward deeper pharmaceutical manufacturing, including the local synthesis of active pharmaceutical ingredients (APIs) and excipients? Is that shift commercially realistic for the country in the foreseeable future?

Moving into Active Pharmaceutical Ingredient (API) production is entirely possible, but it faces major commercial and structural hurdles. With roughly 12 local pharmaceutical plants operating in Ethiopia today, a domestic API facility relying solely on the local market would lack the demand needed to achieve profitability. To be viable, an API plant must operate at a massive scale and meet international regulatory standards so it can supply regional and broader African markets.

Because API manufacturing is exceptionally capital-intensive and offers long-term rather than immediate investment returns, private investors cannot bear the risk alone. At EPHARM, we proactively initiated discussions with prospective Indian partners, prepared detailed proposals, and presented them to financial institutions. However, investors remain hesitant due to the extended payback timeline and unconfirmed export markets.

For API manufacturing to become a reality in Ethiopia, two conditions must be met. First, the downstream domestic pharmaceutical manufacturing sector must expand significantly to provide a larger baseline market. Second, the government must step in with strong policy backing and targeted incentives—far beyond what is offered to standard formulation plants—potentially through Public-Private Partnerships (PPPs). If strong policy incentives, government co-investment, and export market access align, Ethiopia can successfully establish API production.

Looking at the next five years, which medicines does Ethiopia have the strongest realistic opportunity to manufacture competitively, substitute for imports and eventually export?

 

The strongest opportunity lies in the basic essential medicines—most notably commonly used antibiotics and primary care therapeutics that we already produce locally. Health authorities have identified roughly 97 medicines that local manufacturers currently have the capacity to supply adequately, and policy efforts are underway to gradually phase out imports for these products. We may not even need five years to achieve import substitution for this category; with the recent surge in domestic manufacturing activity and plant expansions across the sector, we could meet most of that demand within the next two to three years.

Ethiopia’s achievement of Maturity Level 3 (ML3) status in medicines regulation serves as an important catalyst in this regard. This international benchmark significantly elevates our national regulatory standing, giving domestic manufacturers the credibility required to enter regional export markets.

What policy shifts or government support measures would make the greatest impact on Ethiopia’s pharmaceutical manufacturing sector over the coming years?

 

The biggest difference would come from a predictable, sector-responsive policy framework that recognizes the strategic and capital-intensive nature of pharmaceutical manufacturing.

First, the investment-incentive framework should encourage manufacturers to expand local production, invest in technology and quality standards, and progressively reduce dependence on imported finished medicines. Such incentives should be strategic, predictable and performance-oriented, linked to measurable outcomes such as local production, technology transfer, import substitution and exports.

Second, access to long-term financing and adequate foreign exchange is critical. Pharmaceutical manufacturing requires substantial upfront investment, while active pharmaceutical ingredients, specialized inputs, machinery and spare parts are still largely sourced internationally. The sector therefore needs financing arrangements that reflect its longer investment and working-capital cycle.

Third, policy consistency and effective coordination among government institutions are essential. Investors need confidence that the regulatory and investment environment will remain sufficiently predictable to justify patient capital and continued expansion.

Ethiopia has the market, human capital and an emerging regulatory foundation to build a competitive pharmaceutical industry. With consistent implementation, appropriate financing and strong partnership between government, manufacturers and financial institutions, the country can build a resilient pharmaceutical manufacturing base—strengthening health security, reducing import dependence, creating skilled employment and ultimately positioning Ethiopia as a competitive pharmaceutical manufacturing hub for the region.

 

Ethiopia has the market, human capital, and an emerging regulatory foundation to build a competitive pharmaceutical industry. With consistent implementation, appropriate financing, and strong partnerships between government, manufacturers, and financial institutions, the country can build a resilient pharmaceutical manufacturing base—strengthening health security, reducing import dependence, creating skilled employment, and ultimately positioning Ethiopia as a competitive pharmaceutical manufacturing hub for the region.

ADVERTISEMENT
Mahlet Mehdi

Mahlet Mehdi

Related Posts

Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations:  Security Analyst
Interview

Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations: Security Analyst

September 28, 2026
0

Ethiopia once again finds itself on the brink of another war. Countries such as the United States, Russia, the United Arab Emirates, Japan, and Qatar...

Read moreDetails
Competition, Trapped Funds, and Connectivity: Aviation Guru on Realities in a Fast-Evolving Industry

Competition, Trapped Funds, and Connectivity: Aviation Guru on Realities in a Fast-Evolving Industry

September 5, 2026
Mercy Corps Rethinks Humanitarian Approach as Funding Runs Dry

Mercy Corps Rethinks Humanitarian Approach as Funding Runs Dry

August 5, 2026
Beyond Lifting the Credit Cap

Beyond Lifting the Credit Cap

July 22, 2026
“The Violence is more Visible, more Chaotic, and Harder for the International Community to Ignore,” ECLJ.

“The Violence is more Visible, more Chaotic, and Harder for the International Community to Ignore,” ECLJ.

July 1, 2026
Election Funding has Declined Significantly: Head ofCSOs Coalition for Elections

Election Funding has Declined Significantly: Head ofCSOs Coalition for Elections

May 30, 2026
Current War’s Economic Shock Potentially Surpasses 1973 Oil Embargo: Professor Eric

Current War’s Economic Shock Potentially Surpasses 1973 Oil Embargo: Professor Eric

May 1, 2026
ADVERTISEMENT

Stay Informed. Stay Ahead

Receive in-depth analysis, breaking news, and exclusive reports from Ethiopia and beyond.

Thank you!

You’re almost there! Confirm your subscription to The Reporter Magazine to start receiving exclusive news, analysis, and insights directly in your inbox.

RECOMMENDED

Another Wave of Massacre Targets Orthodox Christians in Arsi; 60 Killed, Says Holy Synod

Another Wave of Massacre Targets Orthodox Christians in Arsi; 60 Killed, Says Holy Synod

October 26, 2026
WFP Reports USD251 million Funding Gap as it Plans Relief for Over 220,000 People Across Three Regions in Ethiopia

WFP Reports USD251 million Funding Gap as it Plans Relief for Over 220,000 People Across Three Regions in Ethiopia

October 23, 2026
Ethiopia Receives 12 Russian Su-35 Fighter Jets, Plans to Acquire Four S-400 Systems Batteries

Ethiopia Receives 12 Russian Su-35 Fighter Jets, Plans to Acquire Four S-400 Systems Batteries

October 28, 2026
Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations:  Security Analyst

Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations: Security Analyst

September 28, 2026
Ethiopia Ranks Among World’s Lowest-Ranked Nations in Rule of Law Index as Score Slides to 0.36

Ethiopia Ranks Among World’s Lowest-Ranked Nations in Rule of Law Index as Score Slides to 0.36

October 22, 2026

MOST VIEWED

  • Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations:  Security Analyst

    Washington Has Sent a Sufficient Signal to PM Abiy on Military Operations: Security Analyst

    237 shares
    Share 95 Tweet 59
  • WFP Reports USD251 million Funding Gap as it Plans Relief for Over 220,000 People Across Three Regions in Ethiopia

    30 shares
    Share 12 Tweet 8
  • Local Pharma Production Is a Matter of Sovereignty: Dr. Mohammed Nuri

    28 shares
    Share 11 Tweet 7
  • Another Wave of Massacre Targets Orthodox Christians in Arsi; 60 Killed, Says Holy Synod

    27 shares
    Share 11 Tweet 7
  • GCL, Jurong to Build Second Phase of Calub LNG Project in Somali Region

    25 shares
    Share 10 Tweet 6
The Reporter Magazine

The Reporter Magazine
Media & Communications Center
Addis Ababa, Ethiopia
(+251) 116 61 61 85
[email protected]

CATEGORY

  • Agenda
  • Art and Culture
  • Bottom Line
  • Brief
  • By the Numbers
  • Commentary
  • Dossier
  • Economy
  • Editorial
  • Ethio-Startups
  • Features
  • For the Record
  • Global Addis
  • Interview
  • Life
  • Money Talks
  • Op-ed
  • Recap
  • Sponsored
  • The Month in Brief
  • The View
  • Travel
  • Uncategorized
  • Video

Tags

Addis Ababa Afar Africa African Art Coffee coronavirus Covid-19 Cross-border economy Dallol Economy election 2020 Epiphany EPRDF Eritrean currency Erta Ale Ertale Ethiopia Ethiopia–Egypt relations Federalists GERD Global Economy GMO Gondar Gullele Botanic Garden HERITAGE Horn of Africa geopolitics IGAD Inflation Informal trade lockdown Microfinance Nakfa Nile Oscar Piazza politics Red Sea security Somalia Somaliland Startup Survival economy Tigray post-war U.S. foreign policy in Africa unemployment
  • Magazine Archive
  • Terms & Conditions
  • Privacy Policy
  • Contact Us
  • Our Team
  • About Us

Copyright © 2026 Media & Communications Center. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepage
  • Interview
  • Op-ed
  • Commentary
  • The Month in Brief
  • Economy
  • Agenda
  • Life
  • Ethio-Startups
  • Art and Culture
  • The View
  • Editorial
  • Recap
  • Magazine Archive

Copyright © 2026 Media & Communications Center. All Rights Reserved